143 related articles for article (PubMed ID: 22158031)
1. Using non-coding small RNAs to develop therapies for Huntington's disease.
Zhang Y; Friedlander RM
Gene Ther; 2011 Dec; 18(12):1139-49. PubMed ID: 22158031
[TBL] [Abstract][Full Text] [Related]
2. Sustained effects of nonallele-specific Huntingtin silencing.
Drouet V; Perrin V; Hassig R; Dufour N; Auregan G; Alves S; Bonvento G; Brouillet E; Luthi-Carter R; Hantraye P; Déglon N
Ann Neurol; 2009 Mar; 65(3):276-85. PubMed ID: 19334076
[TBL] [Abstract][Full Text] [Related]
3. Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts.
van Bilsen PH; Jaspers L; Lombardi MS; Odekerken JC; Burright EN; Kaemmerer WF
Hum Gene Ther; 2008 Jul; 19(7):710-9. PubMed ID: 18549309
[TBL] [Abstract][Full Text] [Related]
4. Increased Steady-State Mutant Huntingtin mRNA in Huntington's Disease Brain.
Liu W; Chaurette J; Pfister EL; Kennington LA; Chase KO; Bullock J; Vonsattel JP; Faull RL; Macdonald D; DiFiglia M; Zamore PD; Aronin N
J Huntingtons Dis; 2013; 2(4):491-500. PubMed ID: 25062733
[TBL] [Abstract][Full Text] [Related]
5. Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA.
Wang YL; Liu W; Wada E; Murata M; Wada K; Kanazawa I
Neurosci Res; 2005 Nov; 53(3):241-9. PubMed ID: 16095740
[TBL] [Abstract][Full Text] [Related]
6. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients.
Pfister EL; Kennington L; Straubhaar J; Wagh S; Liu W; DiFiglia M; Landwehrmeyer B; Vonsattel JP; Zamore PD; Aronin N
Curr Biol; 2009 May; 19(9):774-8. PubMed ID: 19361997
[TBL] [Abstract][Full Text] [Related]
7. Allele-specific silencing of mutant Huntington's disease gene.
Zhang Y; Engelman J; Friedlander RM
J Neurochem; 2009 Jan; 108(1):82-90. PubMed ID: 19094060
[TBL] [Abstract][Full Text] [Related]
8. Huntingtin-lowering strategies in Huntington's disease: antisense oligonucleotides, small RNAs, and gene editing.
Aronin N; DiFiglia M
Mov Disord; 2014 Sep; 29(11):1455-61. PubMed ID: 25164989
[TBL] [Abstract][Full Text] [Related]
9. Nucleic Acid Therapeutics in Huntington's Disease.
Singh K; Roy I
Recent Pat Biotechnol; 2019; 13(3):187-206. PubMed ID: 30747088
[TBL] [Abstract][Full Text] [Related]
10. Allele-specific silencing of mutant huntingtin in rodent brain and human stem cells.
Drouet V; Ruiz M; Zala D; Feyeux M; Auregan G; Cambon K; Troquier L; Carpentier J; Aubert S; Merienne N; Bourgois-Rocha F; Hassig R; Rey M; Dufour N; Saudou F; Perrier AL; Hantraye P; Déglon N
PLoS One; 2014; 9(6):e99341. PubMed ID: 24926995
[TBL] [Abstract][Full Text] [Related]
11. Self-duplexing CUG repeats selectively inhibit mutant huntingtin expression.
Fiszer A; Olejniczak M; Galka-Marciniak P; Mykowska A; Krzyzosiak WJ
Nucleic Acids Res; 2013 Dec; 41(22):10426-37. PubMed ID: 24038471
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional dysregulation of coding and non-coding genes in cellular models of Huntington's disease.
Bithell A; Johnson R; Buckley NJ
Biochem Soc Trans; 2009 Dec; 37(Pt 6):1270-5. PubMed ID: 19909260
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of mutant huntingtin expression by RNA duplex targeting expanded CAG repeats.
Fiszer A; Mykowska A; Krzyzosiak WJ
Nucleic Acids Res; 2011 Jul; 39(13):5578-85. PubMed ID: 21427085
[TBL] [Abstract][Full Text] [Related]
14. [Gene silencing approaches for the treatment of Huntington's disease].
Merienne N; Déglon N
Med Sci (Paris); 2015 Feb; 31(2):159-67. PubMed ID: 25744262
[TBL] [Abstract][Full Text] [Related]
15. Animal models of Huntington's disease: implications in uncovering pathogenic mechanisms and developing therapies.
Wang LH; Qin ZH
Acta Pharmacol Sin; 2006 Oct; 27(10):1287-302. PubMed ID: 17007735
[TBL] [Abstract][Full Text] [Related]
16. Huntington's disease does not appear to increase the risk of diabetes mellitus.
Boesgaard TW; Nielsen TT; Josefsen K; Hansen T; Jørgensen T; Pedersen O; Nørremølle A; Nielsen JE; Hasholt L
J Neuroendocrinol; 2009 Sep; 21(9):770-6. PubMed ID: 19602103
[TBL] [Abstract][Full Text] [Related]
17. Identification and characterization of the miniature pig Huntington's disease gene homolog: evidence for conservation and polymorphism in the CAG triplet repeat.
Matsuyama N; Hadano S; Onoe K; Osuga H; Showguchi-Miyata J; Gondo Y; Ikeda JE
Genomics; 2000 Oct; 69(1):72-85. PubMed ID: 11013077
[TBL] [Abstract][Full Text] [Related]
18. The number of CAG repeats within the normal allele does not influence the age of onset in Huntington's disease.
Klempíř J; Zidovská J; Stochl J; Ing VK; Uhrová T; Roth J
Mov Disord; 2011 Jan; 26(1):125-9. PubMed ID: 21322024
[TBL] [Abstract][Full Text] [Related]
19. Delivering a disease-modifying treatment for Huntington's disease.
Godinho BM; Malhotra M; O'Driscoll CM; Cryan JF
Drug Discov Today; 2015 Jan; 20(1):50-64. PubMed ID: 25256777
[TBL] [Abstract][Full Text] [Related]
20. Experimental models of HD and reflection on therapeutic strategies.
Kim J; Bordiuk OL; Ferrante RJ
Int Rev Neurobiol; 2011; 98():419-81. PubMed ID: 21907096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
